BioCorRx Inc (BICX)
OTHER OTC:BICX
Want to see BICX full AI Analyst Report?
BICX Stock Chart & Stats
$0.32
$0.00(0.00%)
At close: 4:00 PM EST
$0.32
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.20 - $1.28
Previous CloseN/A
Volume44.00
Average Volume (3M)824.00
Market Cap
$11.62M
Enterprise Value$10.25M
Total Cash (Recent Filing)$211.91K
Total Debt (Recent Filing)$2.12M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding29,055,548
10 Day Avg. Volume1,315
30 Day Avg. Volume824
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.48
Price to Sales (P/S)6.75
P/FCF Ratio-2.34
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue11.69
Enterprise Value/Gross Profit13.93
Enterprise Value/Ebitda-3.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$971.85K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue expansion, including a 2025 step-up (+103%) and TTM growth, indicates improving market traction for treatment offerings. Over 2-6 months this supports scaling potential and the opportunity to leverage fixed cost absorption toward breakeven as revenue base increases.
Solid Gross MarginA ~65% gross margin implies the core treatment and services generate strong per-unit profitability, giving management room to invest in distribution and patient services. If operating expenses are controlled, this margin can help the company move toward sustainable profitability over the medium term.
Subsidiary ReorganizationThe March 2026 equity-exchange gives BioCorRx tax-efficient parent control of its pharma subsidiary without cash outlay, increasing strategic flexibility. Consolidated ownership can simplify governance, streamline decision-making, and enable integrated commercialization or licensing strategies longer term.
Bears Say
Large Operating & Net LossesVery large operating and net losses far exceed current revenue, signaling the business is not near profitability. Persisting high losses will require ongoing financing and make it hard to achieve sustainable free cash flow without significant structural cost cuts or material revenue acceleration.
Negative Cash Flow / Cash BurnConsistent negative operating and free cash flow indicate the company is burning cash relative to its revenue base. Over months this elevates refinancing risk and the likelihood of dilution or asset sales if cash needs grow, constraining investments in growth initiatives and operational scaling.
Deeply Negative EquityDeep negative equity reflects accumulated losses and a weak capital structure, reducing borrowing capacity and investor confidence. Structural balance-sheet weakness increases the probability of future dilution, debt restructuring, or constraints on strategic options over the medium term.
BioCorRx News
BICX FAQ
What was BioCorRx Inc’s price range in the past 12 months?
BioCorRx Inc lowest stock price was $0.20 and its highest was $1.28 in the past 12 months.
What is BioCorRx Inc’s market cap?
BioCorRx Inc’s market cap is $11.62M.
When is BioCorRx Inc’s upcoming earnings report date?
BioCorRx Inc’s upcoming earnings report date is Aug 17, 2026 which is in 86 days.
How were BioCorRx Inc’s earnings last quarter?
BioCorRx Inc released its earnings results on Aug 14, 2025. The company reported -$0.07 earnings per share for the quarter, the consensus estimate of -$0.07 by $0.
Is BioCorRx Inc overvalued?
According to Wall Street analysts BioCorRx Inc’s price is currently Overvalued.
Does BioCorRx Inc pay dividends?
BioCorRx Inc does not currently pay dividends.
What is BioCorRx Inc’s EPS estimate?
BioCorRx Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioCorRx Inc have?
BioCorRx Inc has 29,055,548 shares outstanding.
What happened to BioCorRx Inc’s price movement after its last earnings report?
BioCorRx Inc reported an EPS of -$0.07 in its last earnings report, expectations of -$0.07. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioCorRx Inc?
Currently, no hedge funds are holding shares in BICX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioCorRx Inc
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
Technical Analysis
American Shared Hospital Services
―
Concord Medical Services
―
Cryo-Cell International
―
Oncology Institute
―
COMPASS Pathways
―